Somewhat Positive Media Coverage Somewhat Unlikely to Affect Fresenius Medical Care Corporation (FMS) Share Price
News coverage about Fresenius Medical Care Corporation (NYSE:FMS) has trended somewhat positive this week, according to Accern. Accern scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fresenius Medical Care Corporation earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.0712936881265 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment’s analysis:
- Renal dialysis Market Comprehensive Analysis & is to Grow USD 26.6 billion till 2023 at a CAGR of 7.1% (abnewswire.com)
- Hemodialysis & Peritoneal Dialysis Market: 2017 Global Industry Trends, Growth, Share, Size and 2022 Forecast Report (medgadget.com)
- Medical Device Security Market 2017: By Technology Type, End User, Application & Region (finanznachrichten.de)
- Head-To-Head Analysis: Fresenius Medical Care Corporation (FMS) versus The Joint Corp. (JYNT) (americanbankingnews.com)
A number of analysts recently commented on FMS shares. Zacks Investment Research upgraded shares of Fresenius Medical Care Corporation from a “sell” rating to a “hold” rating and set a $53.00 price target on the stock in a research note on Monday, October 9th. Nord/LB restated a “buy” rating on shares of Fresenius Medical Care Corporation in a research note on Wednesday, June 28th. Royal Bank Of Canada restated a “neutral” rating on shares of Fresenius Medical Care Corporation in a research note on Tuesday, August 1st. BidaskClub cut shares of Fresenius Medical Care Corporation from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Finally, DZ Bank AG restated a “buy” rating on shares of Fresenius Medical Care Corporation in a research note on Monday, August 7th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $48.50.
Shares of Fresenius Medical Care Corporation (NYSE FMS) opened at 48.49 on Thursday. The firm has a 50-day moving average of $48.34 and a 200 day moving average of $46.97. The stock has a market capitalization of $29.76 billion, a PE ratio of 20.81 and a beta of 0.48. Fresenius Medical Care Corporation has a 1-year low of $38.05 and a 1-year high of $50.22.
Fresenius Medical Care Corporation (NYSE:FMS) last issued its quarterly earnings results on Tuesday, August 1st. The company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.53 by ($0.05). Fresenius Medical Care Corporation had a net margin of 7.06% and a return on equity of 11.57%. The firm had revenue of $4.47 billion for the quarter, compared to analysts’ expectations of $5.20 billion. During the same period in the prior year, the firm earned $0.96 EPS. Fresenius Medical Care Corporation’s revenue for the quarter was up 11.1% compared to the same quarter last year. Analysts predict that Fresenius Medical Care Corporation will post $2.35 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Fresenius Medical Care Corporation (FMS) Share Price” was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-fresenius-medical-care-corporation-fms-share-price/1639832.html.
About Fresenius Medical Care Corporation
Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.
Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.